2,107
Views
36
CrossRef citations to date
0
Altmetric
Research Article

Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer

, , , , , , , & show all
Pages 616-628 | Received 03 Oct 2017, Accepted 22 Jan 2018, Published online: 30 Jan 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Mingliang Fan, Yue Huang, Xinlin Zhu, Jiayu Zheng & Mingwei Du. (2023) Octreotide and Octreotide-derived delivery systems. Journal of Drug Targeting 31:6, pages 569-584.
Read now
Xue-Tao Li, Ming Jing, Fu-Yi Cai, Xue-Min Yao, Liang Kong & Xiao-Bo Wang. (2021) Enhanced antitumour efficiency of R8GD-modified epirubicin plus tetrandrine liposomes in treatment of gastric cancer via inhibiting tumour metastasis. Journal of Liposome Research 31:2, pages 145-157.
Read now
Xue-min Yao, Feng-ju Niu, Liang Kong, Fu-yi Cai, Ming Jing, Min Fu, Jing-jing Liu, Si-yu He, Lu Zhang, Xin-ze Liu, Rui-jun Ju & Xue-tao Li. (2020) GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial–mesenchymal transition. Drug Development and Industrial Pharmacy 46:6, pages 916-930.
Read now
Yuanyuan Wang, Min Fu, Jingjing Liu, Yining Yang, Yibin Yu, Jinyu Li, Weisan Pan, Lei Fan, Guiru Li, Xuetao Li & Xiaobo Wang. (2019) Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. International Journal of Nanomedicine 14, pages 4071-4090.
Read now
Jing-Jing Liu, Wei Tang, Min Fu, Xiao-Qing Gong, Liang Kong, Xue-Min Yao, Ming Jing, Fu-Yi Cai, Xue-Tao Li & Rui-Jun Ju. (2019) Development of R8 modified epirubicin–dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artificial Cells, Nanomedicine, and Biotechnology 47:1, pages 1947-1960.
Read now
Rui-Jun Ju, Li-Min Mu, Xue-Tao Li, Cui-Qing Li, Zhan-Jie Cheng & Wan-Liang Lu. (2018) Development of functional docetaxel nanomicelles for treatment of brain glioma. Artificial Cells, Nanomedicine, and Biotechnology 46:sup1, pages 1180-1190.
Read now

Articles from other publishers (30)

Janske Nel, Kamil Elkhoury, Émilie Velot, Arnaud Bianchi, Samir Acherar, Grégory Francius, Ali Tamayol, Stéphanie Grandemange & Elmira Arab-Tehrany. (2023) Functionalized liposomes for targeted breast cancer drug delivery. Bioactive Materials 24, pages 401-437.
Crossref
Salma T. Rafik, Jayant S. Vaidya, Alexander J. MacRobert & Elnaz Yaghini. (2023) Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies. Journal of Clinical Medicine 12:7, pages 2648.
Crossref
Aliesha Moudgil, Rajesh Salve, Virendra Gajbhiye & Bhushan P. Chaudhari. (2023) Challenges and emerging strategies for next generation liposomal based drug delivery: An account of the breast cancer conundrum. Chemistry and Physics of Lipids 250, pages 105258.
Crossref
Xinliang Sun, Bei Wang, Jie Zhang & Min Li. (2022) Partner-Specific Drug Repositioning Approach Based on Graph Convolutional Network. IEEE Journal of Biomedical and Health Informatics 26:11, pages 5757-5765.
Crossref
Ka Hong Wong, Donglin Yang, Shanshan Chen, Chengwei He & Meiwan Chen. (2022) Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review. Asian Journal of Pharmaceutical Sciences 17:4, pages 475-490.
Crossref
Xinyu Zhou, Fengzhi Suo, Kristina Haslinger & Wim J. Quax. (2022) Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery. Pharmaceutics 14:2, pages 395.
Crossref
Merve Karpuz, Miray İlhan, Hazal Ezgi Gültekin, Emre Ozgenc, Zeynep Şenyiğit & Evren Atlihan-Gundogdu. 2022. Applications of Nanovesicular Drug Delivery. Applications of Nanovesicular Drug Delivery 219 244 .
A.I. Fraguas-Sanchez, C. Martin-Sabroso, A. Fernandez-Carballido & A.I. Torres-Suarez. 2022. Targeted Nanomedicine for Breast Cancer Therapy. Targeted Nanomedicine for Breast Cancer Therapy 65 110 .
Sijongesonke Peter, Siphesihle Jama, Sibusiso Alven & Blessing A. Aderibigbe. (2021) Artemisinin and Derivatives-Based Hybrid Compounds: Promising Therapeutics for the Treatment of Cancer and Malaria. Molecules 26:24, pages 7521.
Crossref
Jing Wang, Motao Zhu & Guangjun Nie. (2021) Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles. Advanced Drug Delivery Reviews 178, pages 113974.
Crossref
Huai-Song Wang, Xingya Xia, Yingming Wang, Weiping Lyu, Mangmang Sang, Congcong Gu, Wenyuan Liu & Feng Zheng. (2021) Anti-cancer adjuvant drug screening via epithelial-mesenchymal transition-related aptamer probe. Analytical and Bioanalytical Chemistry 413:28, pages 6951-6962.
Crossref
Ran Yu, Guihua Jin & Manabu Fujimoto. (2021) Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases. Frontiers in Oncology 11.
Crossref
Qi Zhang, Linbo Jin, Quanxin Jin, Qiang Wei, Mingyuan Sun, Qi Yue, Huan Liu, Fangfang Li, Honghua Li, Xiangshan Ren & Guihua Jin. (2021) Inhibitory Effect of Dihydroartemisinin on the Proliferation and Migration of Melanoma Cells and Experimental Lung Metastasis From Melanoma in Mice. Frontiers in Pharmacology 12.
Crossref
Yurong Zheng & Antoine E. Karnoub. (2021) Endocrine regulation of cancer stem cell compartments in breast tumors. Molecular and Cellular Endocrinology 535, pages 111374.
Crossref
Yanmei Ma, Peng Zhang, Qilong Zhang, Xiaofei Wang, Qiong Miao, Xiaolan Lyu, Bo Cui & Honghong Ma. (2021) Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer. Oncology Letters 22:4.
Crossref
Kitboklang Khongsti, Bala Gangadhar Pasupuleti, Bidyadhar Das & Ghanashyam Bez. (2021) 1,2,3-Triazole tethered 1,2,4‑trioxane trimer induces apoptosis in metastatic cancer cells and inhibits their proliferation, migration and invasion. Bioorganic Chemistry 112, pages 104952.
Crossref
Biyao Yang, Bo-ping Song, Shaina Shankar, Anna Guller & Wei Deng. (2021) Recent advances in liposome formulations for breast cancer therapeutics. Cellular and Molecular Life Sciences 78:13, pages 5225-5243.
Crossref
Vrinda Gote, Anantha Ram Nookala, Pradeep Kumar Bolla & Dhananjay Pal. (2021) Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue. International Journal of Molecular Sciences 22:9, pages 4673.
Crossref
Vrinda Gote & Dhananjay Pal. (2021) Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer. Bioengineering 8:4, pages 44.
Crossref
Swapnil Sharma, Akansha Bisht, Sanjana Tewari & Vivek Dave. 2021. Nanopharmaceutical Advanced Delivery Systems. Nanopharmaceutical Advanced Delivery Systems 379 405 .
Si-Yue Tang, Hua Wei & Cui-Yun Yu. (2021) Peptide-functionalized delivery vehicles for enhanced cancer therapy. International Journal of Pharmaceutics 593, pages 120141.
Crossref
Mehran Alavi & Rajender S. Varma. (2020) Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations. International Journal of Biological Macromolecules 164, pages 2197-2203.
Crossref
Manish Kumar, Nithya Shanthi, P.S. Rajnikanth & Arun Kumar Mahato. (2020) Authors Review on Drug Nanocrystals: A Progress to Targeted Delivery. Current Nanomedicine 10:3, pages 248-270.
Crossref
Xiaobo Fan, Hongbo Xu, Fengfeng Zhao, Junlong Song, Yongcan Jin, Chen Zhang & Guoqiu Wu. (2020) Lipid-mimicking peptide decorates erythrocyte membrane for active delivery to engrafted MDA-MB-231 breast tumour. European Journal of Pharmaceutics and Biopharmaceutics 152, pages 72-84.
Crossref
Yue Li, Xiaoyan Zhou, Jiali Liu, Xiaohong Yuan & Qian He. (2020) Therapeutic Potentials and Mechanisms of Artemisinin and its Derivatives for Tumorigenesis and Metastasis. Anti-Cancer Agents in Medicinal Chemistry 20:5, pages 520-535.
Crossref
Liang Kong, Fu‐yi Cai, Xue‐min Yao, Ming Jing, Min Fu, Jing‐jing Liu, Si‐yu He, Lu Zhang, Xin‐ze Liu, Rui‐jun Ju & Xue‐tao Li. (2020) RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply. Cancer Science 111:2, pages 621-636.
Crossref
Jieyi Di, Baotong Zheng, Qingfei Kong, Ying Jiang, Siyao Liu, Yang Yang, Xudong Han, Yuqi Sheng, Yunpeng Zhang, Liang Cheng & Junwei Han. (2019) Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities. Molecular Oncology 13:10, pages 2259-2277.
Crossref
Anna Larocca, Gianluca Toniolo, Silvia Tortorella, Marios Krokidis, Georgia Menounou, Giuseppe Di Bella, Chryssostomos Chatgilialoglu & Carla Ferreri. (2019) The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity. Molecules 24:17, pages 3085.
Crossref
Anna Lichota & Krzysztof Gwozdzinski. (2018) Anticancer Activity of Natural Compounds from Plant and Marine Environment. International Journal of Molecular Sciences 19:11, pages 3533.
Crossref
Enrique Konstat-Korzenny, Jorge Ascencio-Aragón, Sebastian Niezen-Lugo & Rosalino Vázquez-López. (2018) Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer. Medical Sciences 6:1, pages 19.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.